Recent deal offering controlled generics access in limited countries does not go far enough as main patent expires in India today, opening door to more affordable generics. As Johnson & Johnson’s (J&J) 20-year primary patent on the critical, lifesaving drug-resistant tuberculosis (DR-TB) drug bedaquiline expires in majority of countries including India today, Doctors Without Borders/Médecins […]
Read More… from MSF calls again on J&J to withdraw or abandon extended patents on Tuberculosis drug